Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060251 | 0.83 | TSHR (0.71) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3067593 | 0.82 | MEN1 (0.52) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3058477 | 0.81 | TSHR (0.55) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3053493 | 0.77 | PDK1 (0.50) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3050282 | 0.76 | NPC1 (0.61) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3053543 | 0.75 | TSHR (0.59) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3060156 | 0.75 | MAPK14 (0.66) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3057341 | 0.75 | TSHR (0.59) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3054221 | 0.75 | TSHR (0.59) | KMT2AMEN1NPC1TSHRGAA | |
| SCHEMBL3052776 | 0.75 | TSHR (0.59) | KMT2AMEN1NPC1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | KMT2A 1989/4885MEN1 1499/4885NPC1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.